re: $1.00 woosh - new high close The ABN AMRO 19th Aug report puts a DCF valuation of ACL at $2.44 and a price target of $1.15. This is based on a 30% chance of ACL being successful.
They maintain that they will rerate their chance of success to 70% with the successful completion of the cGMP pilot-scale manufacturing plant. (and also their valuation of ACL)
This is due by the end of September, and all indications are that all is going to plan. When this is announced I think there will be a major rerating of this stock. ABN AMROs discounting of the stock down to 30% will be revised to 70% more than doubling their valuation.
No doubt this is the cause of the recent interest in ACL.
re: $1.00 woosh - new high close The ABN AMRO 19th Aug report...
Add TSN (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
1.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $1.409M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
| TSN (ASX) Chart |
Day chart unavailable